ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~9#܈ ~~4#܈ ~~3#܈ ~~"؈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33 NA SIGNATURES"7Item 1 Financial Statements[Income StatementDŽ Cash Flows&NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORY"jNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS#*NOTE 7 INTANGIBLE ASSETS (1)&NOTES TO UNAUDITED CONSOLIDATED&#NOTE 8 OTHER CURRENT LIABILITIE&=9NOTES TO UNAUDITED CONSOLID (1)!GNOTE 10 NET LOSS PER SHARE&VNOTES TO UNAUDITED CONSOLID (2)&fNOTES TO UNAUDITED CONSOLID (3)&B~NOTE 15 COMMITMENTS AND CONTINGResearch and Development&Research and Development ExpensResults of Operations Results of Operations (1) HResults of Operations (2) Results of Operations (3) Results of Operations (4) 5Results of Operations (5)&$Liquidity and Capital Resources3Item 6 Exhibits}OSIGNATURES (1) ^NOTICE&EoI Clientsupplied Materials and EXHIBITProduct Specifications5 EXHIBIT (1)x EXHIBIT (2)&UNIT PRICING FEES AND MINIMUM R&UNIT PRICING FEES AND MINIM (1)&UNIT PRICING FEES AND MINIM (2)&UNIT PRICING FEES AND MINIM (3)Table of ContentsE EXHIBIT (3); EXHIBIT (4)9W EXHIBIT (5)h EXHIBIT (6)*w EXHIBIT (7)P EXHIBIT (8)&8Schedule 7 attached hereto or a&&IN WITNESS WHEREOF the undersig&IN WITNESS WHEREOF the unde (1)&Borrower Representative pursuan&Borrower Representative pur (1)&iBorrower Representative pur (2)&Borrower Representative pur (3) EXHIBIT (9)!Schedule 34 CapitalizationAPATENTS4 EXHIBIT (10)G EXHIBIT (11)] EXHIBIT (12)u EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17)  EXHIBIT (18)Z EXHIBIT (19). EXHIBIT (20)@ EXHIBIT (21)N EXHIBIT (22)\ EXHIBIT (23)i EXHIBIT (24)pv EXHIBIT (25)&IN WITNESS WHEREOF the parties %uIN WITNESS WHEREOF the par (1)D Exhibit 311 Exhibit 312  Exhibit 321 Exhibit 322 l  g  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??P SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 6} $ } !      TherapeuticsMD, Inc. 10-Q 07/30/2018 N/A!Large accelerated filer ?Accelerated filer ? Non-accelerated filer ? # Smaller reporting company ?5 -(Do not check if a smaller reporting company) ! Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$~,{+k_S+=PF0*8X> @  l  0X16  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNAItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ }  } y<} $ }  0     TherapeuticsMD, Inc. 10-Q 07/30/2018 SIGNATURES Page& PART I - FINANCIAL INFORMATION         Item. 1 Financial Statements ~         . &Consolidated Balance Sheets as of June ~  2*30, 2018 (Unaudited) and December 31, 2017-%Consolidated Statements of Operations~ 3+for the Three and Six Months Ended June 30,-%2018 (Unaudited) and 2017 (Unaudited)-%Consolidated Statements of Cash Flows~ :2for the Six Months Ended June 30, 2018 (Unaudited)and 2017 (Unaudited)2*Notes to Consolidated Financial Statements~ Item 2.,$Management's Discussion and Analysis~ V80of Financial Condition and Results of OperationsItem 3.0(Quantitative and Qualitative Disclosures~ about Market RisksD ltL u9KP[#CJ !"#$%&'()*+,-./  Item 4. Controls and Procedures ~ !!!!!#"PART II - OTHER INFORMATION""#####$$Item 1.$Legal Proceedings$~ $%%%%%&&Item 1A.& Risk Factors&~ &'''''((Item 6.(Exhibits(~ ()))))** SIGNATURES**~ *+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,h)[ D=PF0*8X> @*//..--""  l  >LZ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 8} $ } y} $ } y} $ >                                 TherapeuticsMD, Inc. 10-Q 07/30/2018$Item 1. Financial StatementsJune 30, December 31,  ~  ~     (Unaudited)        ASSETS Current Assets:     Cash~ $~ 2O-%Accounts receivable, net of allowance~ bW~ 57/for doubtful accounts of $418,604 and $380,580, respectively Inventory~ r~ ZOther current assets~ Z=~ Total current assets~ 2'~ bE!Fixed assets, net~ ڡ~  Other Assets:Intangible assets, net~ F~ 1"Prepaid expenses-long term~ V. -Security deposit~ / ~ r|Total other assets~ "q ~  Total assets~ *(~ Z&"+#LIABILITIES AND STOCKHOLDERS EQUITYD5 lznbO=5-@[LJ ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < =  Current Liabilities:        !Accounts payable!~ !bu!!~ !!6".Accrued expenses and other current liabilities""~ "=U"""~ "2"!#Total current liabilities##~ #J###~ #-#$$$$$$$$$%Long-term Liabilities:%%%%%%%%&Long-term debt&&~ &0p&&& &-&#'Total long-term liabilities''~ '0p''' '-'(Total liabilities((~ (F~(((~ (-()))))))))0*(Commitments and Contingencies - See Note********~ +>,,,,,,,,,-Stockholders' Equity:--------6..Preferred stock - par value $0.001; 10,000,000.. .-... .-.//'shares authorized; no shares issued and0 outstanding41,Common stock - par value $0.001; 350,000,000111111112shares authorized:.3&216,834,059 and 216,429,642 issued and33~ 3 < 333~ 35 3!4outstanding, respectively"5Additional paid-in capital55~ 5s\|555~ 5{56Accumulated deficit66~ 6M666~ 6B3У6"7Total stockholders' equity77~ 7|777~ 7728*Total liabilities and stockholders' equity8~ 8*(88~ 8Z&"89:$;____________________________1<)Created by Morningstar Document Research.0=(http://documentresearch.morningstar.com/@ Dz{{mN)=PF0*8X> @==<<;;8888!!!!     l  ,{  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial Statements Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 0} $ }  } $ }  }  $ } y} $ } y} $ ,     TherapeuticsMD, Inc. 10-Q 07/30/2018Income StatementThree Months Ended  Six Months Ended   June 30,  June 30,  ~  ~  ~  ~   Revenues, net ~    ~ m  ~ J  ~                    Cost of goods sold  ~ F   ~ )   ~ dB   ~ Q  Gross profit~ ~   ~    ~ &Ϥ     Operating expenses:     *"Sales, general, and administration~ J~ |  ~  n   ~  Research and development~ ~   ~  L  ~ N~%Depreciation and amortization~ ~ ?  ~    ~ GTotal operating expense~ t~ !  ~  rM  ~ Vr      Operating loss~ € ~ VE  ~  :;  ~ zx2     Other income (expense):     Miscellaneous income~ zf~    ~  n'  ~ :Accreted interest -~ ;    -  ~ NxInterest expense~ * -  ~  *   -$Total other (expense) income~ ~ T   ~  *  ~ A     Loss before taxes~ bx~ .O  ~  C  ~ C     DSlznP Abl*G_| !"#$%&'()*+" Provision for income taxes   -    -    -    - !!!!!!!!!! ! ! ! ! !!!"Net loss"~ "bx""~ ".O"" ~ " C" " ~ "C"########## # # # # ###-$%Net loss per share, basic and diluted$$333333ÿ$$$$$ $ HzGѿ$ $ $ɿ$%%%%%%%%%% % % % % %%%0&(Weighted average number of common shares&&~ &ꪦ3&&&~ &}0&& & ~ & n.3& & &~ &j/&' outstanding($)____________________________1*)Created by Morningstar Document Research.0+(http://documentresearch.morningstar.com/sJ-1=PF0*8X> @++**))$$$$$$ $$"""""" ""          l  3]*  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 7} $ } } $ } } $ 3                                 TherapeuticsMD, Inc. 10-Q 07/30/2018 Cash FlowsSix Months Ended   June 30,  June 30,  ~  ~      , $CASH FLOWS FROM OPERATING ACTIVITIES     Net loss ~ C  ~ C 0(Adjustments to reconcile net loss to net0(cash flows used in operating activities:$Depreciation of fixed assets~ ~ "6)!Amortization of intangible assets~ ~ 5-Provision for (recovery of) doubtful accounts~ "R~  Share-based compensation~ ~ v=0(Amortization of deferred financing costs~ . -4,Changes in operating assets and liabilities:Accounts receivable~ ^~ JD Inventory~ ~ cOther current assets~  ~ ^lAccounts payable~ b\~ B-Accrued interest~  -6.Accrued expenses and other current liabilities~ ~ j-%Net cash used in operating activities~ N]~ * ,$CASH FLOWS FROM INVESTING ACTIVITIES Patent costs~ .x~ :D+lt@x$d6ba ! " # $ % & ' ( ) * + , - . / 0 1 2  Purchase of fixed assets  ~ 5   ~  #!Payment of security deposit!!~ !L!!! !-!-"%Net cash used in investing activities""~ "V"""~ "`"#########,$$CASH FLOWS FROM FINANCING ACTIVITIES$$$$$$$$%Proceeds from term loan%%~ %%%% %-%*&"Payment of deferred financing fees&&~ &j&&& &-&)'!Proceeds from exercise of options''~ 'D'''~ '" '*("Proceeds from exercise of warrants(( (-(((~ (^(1))Net cash provided by financing activities))~ )h?)))~ )~)*********#+Increase (decrease) in cash++~ +I+++~ +@+!,Cash, beginning of period,,~ ,2O,,,~ ,V4\,-Cash, end of period-~ -$--~ -u-./$0____________________________11)Created by Morningstar Document Research.02(http://documentresearch.morningstar.com/* hxY]F$ `=PF0*8X> @b 221100----       l  0  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } I } :      TherapeuticsMD, Inc. 10-Q 07/30/201891NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESLevel 12*unadjusted quoted prices in active markets  , $for identical assets or liabilities;  Level 27 /quoted prices for similar assets or liabilities  7 /in active markets or inputs that are observable  3 +for the asset or liability, either directly  3 +or indirectly through market corroboration,80for substantially the full term of the financialinstrument; andLevel 37/unobservable inputs for the asset or liability.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2qeYMVe`TH =PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } $ }  } $ } $} $                    TherapeuticsMD, Inc. 10-Q 07/30/2018NOTE 4 INVENTORYJune 30, December 31,  ~  ~  Finished product ~ rd  ~ Z  Work in process  ~      -   TOTAL INVENTORY ~ r  ~ Z  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznvtL=PF0*8X> @Z        l  7  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <(} $ } y} $ }  } $                       TherapeuticsMD, Inc. 10-Q 07/30/2018#NOTE 5 OTHER CURRENT ASSETSJune 30, December 31,  ~  ~ ) !Prepaid sales and marketing costs ~ 2  ~ E  Debt financing fees  ~ rE    -  Prepaid insurance  ~ Z    ~ ΄)  Other prepaid costs  ~ 3   ~  Prepaid vendor deposits~ +~ n' TOTAL OTHER CURRENT ASSETS~ Z=~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.w{ocZWM=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } I"} $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 07/30/2018 NOTE 6 FIXED ASSETS, NETJune 30, December 31,  ~  ~  Accounting system ~ `  ~ `   Equipment  ~ f|   ~   Furniture and fixtures  ~    ~   Computer hardware  ~ N   ~ N Leasehold improvements~ P~ P~ J/4~ d1 Accumulated depreciation~ r~ H$ TOTAL FIXED ASSETS, NET~ ڡ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2z~rfmngo=PF0*8X> @Z      l  -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } a/} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 07/30/2018 NOTE 7 INTANGIBLE ASSETS June 30, 2018   Gross Carrying Amount  Accumulated Amortization  Net  Weighted- Average           Amount , $Remaining Amortization Period (yrs.)& Amortizable intangible assets:         OPERA ? software patent ~ >  ~ k  ~ _    &@ . &Development costs of corporate website  ~ ~   ~ f    -    n/a /'Approved hormone therapy drug candidate~ ye~ j  ~  ;X  -@patents.&Hormone therapy drug candidate patents~ Fl -  ~  Fl   n/a (pending)*"Non-amortizable intangible assets:     Multiple trademarks~ L -  ~  L   indefinite Total~ U~  ~  F  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 ~rf58lrs`fQcu=PF0*8X> @       l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } a/} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 07/30/2018 NOTE 7 INTANGIBLE ASSETSDecember 31, 2017   Gross Carrying Amount  Accumulated Amortization  Net  Weighted- Average           Amount , $Remaining Amortization Period (yrs.)& Amortizable intangible assets:         OPERA ? software patent ~ >  ~ f{  ~ n    '@ . &Development costs of corporate website  ~ ~   ~ f    -    n/a /'Approved hormone therapy drug candidate~ N~   ~  vD  ~ >patents.&Hormone therapy drug candidate patents~ fi -  ~  fi   n/a (pending)*"Non-amortizable intangible assets:     Multiple trademarks~ < -  ~  <   indefinite Total~ ~ c ~  1  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 ~rf14hns`fQcu=PF0*8X> @       l   #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Year Ending Estimated  December 31,   Amortization  2018(6 months)  ~   ~   ~   ~   ~   ~   ~  ~ ~  Thereafter~ T>$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.SnbVJ~2N=PF0*8X> @j        l  b8  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 0} $ } y} $ } y} $                               TherapeuticsMD, Inc. 10-Q 07/30/2018( NOTE 8 OTHER CURRENT LIABILITIESJune 30, December 31,  ~  ~ / 'Accrued payroll, bonuses and commission ~ q  ~   costs) !Allowance for coupons and returns  ~ 6m   ~ :tW ) !Accrued sales and marketing costs  ~ j7V   ~   $Accrued compensated absences~ u?~ ƴ9,$Accrued legal and accounting expense~ 2)~ z$( Accrued research and development~ ~ VeAccrued interest~  - Accrued rent~ b~ Other accrued expenses~ V~  Accrued rebates~  ~ ֱ0(Allowance for wholesale distributor fees~  ~  Accrued royalties -~ ,$ TOTAL OTHER CURRENT LIABILITIES~ =U~ 2$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/> 0vj^O>lqlT=PF0*8X> @Z      l  lF  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIENOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } '} $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSJune 30,  ~   Term Loan ~  (  Debt discount and financing fees  ~  !  Total long-term debt ~ 0p  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TnbVJ_=PF0*8X> @:    l  XU  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} $ } } $ } } $                     TherapeuticsMD, Inc. 10-Q 07/30/2018"NOTE 10 NET LOSS PER SHARE"Three and six months ended   June 30,  June 30,  ~  ~   Stock options  ~ N   ~ Y  Warrants  ~ N   ~ .    ~ Q   ~ ևR $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h|pd&5)=PF0*8X> @B     l  e  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U} $ } <} $} $ } <} $                       TherapeuticsMD, Inc. 10-Q 07/30/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Six Months Six Months   Ended  Ended   June 30,  June 30,  ~  ~  Risk-free interest rate    2.38-2.63%     1.84-2.01%   Volatility    61.82-64.04%     61.56-63.95% Term (in years)5.1-6.255.5-6.25Dividend yield~  %~  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.UnbVJh(x=PF0*8X> @Z        l   }  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } I"} $ } }  $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS1)Number of Shares Underlying Stock Options'Weighted Average Exercise Price  Weighted !Aggregate Intrinsic Value           Average            Remaining            Contractual            Life in Years$ Balance at December 31, 2017  ~    = ףp=@    Q@  ~ j Granted~ S ףp= @      Exercised~ NRQ@     ~ .TExpired/Forfeited~ Z3q= ףp@      Balance at June 30, 2018~ N\(\@   p= ף@  ~ @t!Vested and Exercisable at      June 30, 2018~ 0Gz @   333333@  ~ Z3!Unvested at June 30, 2018~ ʏQ@   Q!@  ~ R $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/82 nbVJu]=]-\sg?=PF0*8X> @     l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } I"} $ } y} $      TherapeuticsMD, Inc. 10-Q 07/30/2018-%NOTE 15 COMMITMENTS AND CONTINGENCIES!Years Ending December 31, 2018 (6 months) ~ ށ ~   ~ B ~   ~ C ~   ~ ^9 ~    - $Total minimum lease payments~ ~$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|}qeY[vN=PF0*8X> @*  l  'ע  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTING!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $}  } m} <} m}  '     TherapeuticsMD, Inc. 10-Q 07/30/2018 Research and Development6.Replenish Trial Co-Primary Efficacy Endpoints:0 (Mean Change in Frequency and Severity of4 ,Hot Flashes Per Week Versus Placebo at Weeks% 4 and 12, VMS-MITT Population            Estradiol/Progesterone 1 mg/100 mg 0.5 mg/100 mg 0.5 mg/50 mg 0.25 mg/50 mgPlacebo (n = 141) (n = 149) (n = 147) (n = 154) (n = 135) Frequency%Week 4 P-value versus placebo9v??5^I ?MbP? -&Week 12 P-value versus placeboMb`? -Severity%Week 4 P-value versus placeboX9v?{Gzt?Dl?? -&Week 12 P-value versus placebo;On?~jt? -0(Replenish Trial Primary Safety Endpoint:6.Incidence of Consensus Endometrial Hyperplasia2*or Malignancy up to 12 months, EndometrialSafety Population?Dm l~rf,Oqlg !"#$%&      !Endometrial Hyperplasia! 0% (0/280)! 0% (0/303)! 0% (0/306)! 0% (0/274)! 0% (0/92)"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/ x(=PF0*8X> @Z &&%%$$    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and DevelopmentResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} $ }  } $ }  }  $ } } $ }  } $      TherapeuticsMD, Inc. 10-Q 07/30/2018)!Research and Development ExpensesThree Months Ended  Six Months Ended   June 30,  June 30,  ~  ~  ~  ~    (000s)  (000s)  TX 001-HR ~ :   ~ T  ~ T  ~ &   TX 002-HR   -    -    -    -  TX 004-HR~ z~ >+  ~  Z1  ~ I&Other research and development~ .~   ~  FR  ~ ", Total~ >j~ 2 ~  :  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0hui]?Jq=PF0*8X> @             l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } !} $ } U} $ } U}  $ } } $                         TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsThree Months Ended     June 30,  ~  ~   Change   (000s)  Revenues, net ~ :  ~ jB  ~ f  Cost of goods sold  ~    ~     ~ r Operating expenses~ 7~ m  ~    Operating loss~  ~ *  ~  1 #Other (expense) income, net~ ~ f  ~   Net loss~ ~  ~  j, $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2uig(t|pd<=PF0*8X> @z          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsThree Months Ended   June 30,  ~  ~ & Research and development costs   333332@ %   B@ %/ 'Human resource related costs, including   fffff5@ %   333338@ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding humanfffffF@ %8@ %resource costs/'Professional fees for legal, accounting@ %ffffff@ %and consulting Other operating expensesffffff @ %!@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4.ui3/f[OC=PF0*8X> @:    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 7} $ }  } $ }  }  $ } } $                            TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsThree Months Ended     June 30,  ~  ~   Change   (000s)& Research and development costs ~ >j  ~ 2  ~  / 'Human resources related costs including  ~ |   ~ fZ   ~ " $salaries, benefits and taxes6.Sales and marketing, excluding human resources~ ~ Y  ~  :  costs/'Professional fees for legal, accounting~ ~   ~  :  and consulting Other operating expenses~ ~.~   ~  ~  Total operating expenses~ 7~ m ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8uig 0\=PF0*8X> @z          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } $ }  } $ }  }  $ } } $                         TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsSix Months Ended     June 30,  ~  ~   Change   (000s)  Revenues, net ~ u  ~   ~   Cost of goods sold  ~    ~    ~  Operating expenses~ ~ .  ~    Operating loss~ y~ }  ~  J Other income, net~ ~ n  ~  j Net loss~ {~  ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2uii*v|pH=PF0*8X> @z          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsSix Months Ended   June 30,  ~  ~ & Research and development costs   5@ %   A@ %/ 'Human resource related costs, including   ffffff6@ %   fffff7@ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding humanE@ %~ r %resource costs/'Professional fees for legal, accounting@ %333333@ %and consulting Other operating expenses@ %333333 @ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4(ui5 1h aUI!=PF0*8X> @:    l  #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 7} $ }  } $ }  }  $ } } $                            TherapeuticsMD, Inc. 10-Q 07/30/2018Results of OperationsSix Months Ended     June 30,  ~  ~   Change   (000s)& Research and development costs ~ :  ~   ~ V / 'Human resources related costs including  ~    ~    ~ - $salaries, benefits and taxes6.Sales and marketing, excluding human resources~ ~   ~    costs/'Professional fees for legal, accounting~ :~ +  ~  . and consulting Other operating expenses~ rO~ <  ~  v  Total operating expenses~ ~ . ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8uii 2^=PF0*8X> @z          l  2  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)Item 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 1} $                      TherapeuticsMD, Inc. 10-Q 07/30/2018'Liquidity and Capital ResourcesSix Months Ended   June 30,  ~  ~    (000s)- %Net cash used in operating activities ~ &G  ~ ڣ - %Net cash used in investing activities ~ R  ~  1)Net cash provided by financing activities~ Zj~ >$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|wk_+=PF0*8X> @r         l  +JO  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } y } $ } } $ } I; +     TherapeuticsMD, Inc. 10-Q 07/30/2018Item 6. ExhibitsExhibit Date Description  10.1+  April 20, 2016 , $Softgel Commercial Supply Agreement,     / 'by and between TherapeuticsMD, Inc. and     ' Catalent Pharma Solutions, LLC.  10.2+   May 1, 2018 3 +Credit and Security Agreement, by and among     . &TherapeuticsMD, Inc., as borrower, its/'subsidiaries party thereto from time to2*time, each as a borrower, MidCap Financial91Trust, as agent and as lender, and the additional0(lenders party thereto from time to time. 10.3* May 9, 20185-Fourth Amendment to Lease between the Company#and 6800 Broken Sound, LLC. 31.1* July 30, 20180(Certification of Chief Executive Officer5-pursuant to Rule 13a-14(a) and Rule 15d-14(a) 31.2* July 30, 20180(Certification of Chief Financial Officer5-pursuant to Rule 13a-14(a) and Rule 15d-14(a) 32.1* July 30, 20185-Section 1350 Certification of Chief ExecutiveOfficer 32.2* July 30, 20185-Section 1350 Certification of Chief FinancialOfficer101.INS* n/aXBRL Instance Document101.SCH* n/a/'XBRL Taxonomy Extension Schema Document101.CAL* n/a4,XBRL Taxonomy Extension Calculation LinkbaseDocumentD lzn"8[p{!*T~ !"#$%&'()*  101.DEF*  n/a 3 +XBRL Taxonomy Extension Definition Linkbase!!!!!!Instance Document""101.LAB*" "n/a"."&XBRL Taxonomy Extension Label Linkbase######Instance Document$$101.PRE*$ $n/a$,$$XBRL Taxonomy Extension Presentation%%%%%"%Linkbase Instance Document&'$(____________________________1))Created by Morningstar Document Research.0*(http://documentresearch.morningstar.com/)W~rf>=PF0*8X> @**))(( l  I^  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsNOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } } U5      TherapeuticsMD, Inc. 10-Q 07/30/2018 SIGNATURESTHERAPEUTICSMD, INC.    By: /s/ Robert G. Finizio   Robert G. Finizio   Chief Executive Officer  % (Principal Executive Officer) By:!/ s/ Daniel A. CartwrightDaniel A. CartwrightChief Financial Officer4,(Principal Financial and Accounting Officer)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6tH0C+x(=PF0*8X> @" l  n  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } 1      TherapeuticsMD, Inc. 10-Q 07/30/2018NOTICE To Client:TherapeuticsMD, Inc. 1 )6800 Broken Sound Parkway NW, Third Floor ! Boca Raton, Florida 33487  Attn: President With a copy to:0 (Chief Legal Counsel at the above address   To Catalent:&Catalent Pharma Solutions, LLC2725 Scherer Drive N. St. Petersburg, FL 33716 Attn: President, SoftgelWith a copy to:!Catalent Pharma Solutions14 Schoolhouse RoadSomerset, NJ 088730(Attn: General Counsel (Legal Department)$Facsimile: +1 (732) 537-6491$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0xBZBs[RF:=PF0*8X> @ l   A  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U5} } 0      TherapeuticsMD, Inc. 10-Q 07/30/2018D<I. Client-supplied Materials (and associated specifications) TestAcceptance CriteriaAnalytical Method  Appearance [***] [***] Identification A (IR) [***] [***] Identification B (UV) [***] [***]  Melting range [***] [***] Specific rotation [***] [***] Water [***] [***] Assay (HPLC) [***] [***]Microbial limits [***]-%Total aerobic microbial count (TAMC): [***]4,Total combined yeasts and mold count (TYMC): [***]Escherichia in 1 g [***]"Related substances (HPLC): [***] [***]Estrone (Ph.Eur.A) 17?-estradiol (Ph.Eur.B) [***]#?9(11)-estradiol (Ph.Eur.D) [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/DlfZNB{8QE i:OC7=PF0*8X> @ l  V  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and Product Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m)} } 0      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT TestAcceptance CriteriaAnalytical Method 4-Cl-estradiol [***] ' Individual unspecified impurity [***] Total impurities [***] Residual Solvents (GC): [***] [***] 1   BenzeneDichloromethane [***]Ethanol [***] Ethyl acetate [***]Methanol [***]Pyridine [***]Tetrachloroethylene [***] Acetic acid [***] [***][***] 2*"Particle size by laser diffraction$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<:w+D nI_=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBIT EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <(}       TherapeuticsMD, Inc. 10-Q 07/30/2018Product Specifications TestMethodLimits  Appearance [***] [***]& Estradiol Assay (4 ?g/capsule) [***] [***]) !Related Compounds (Tested at RTP) [***] [***]   [***]   [***] [***] [***] Dissolution [***] [***] [***] [***] [***]Moisture Content [***] [***]!Total Aerobic Plate Count [***] [***]%Total Combined Yeast and Mold [***] [***] P. aeruginosa [***] [***] S. aureus [***] [***]Candida albicans [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BXth4a8[2 9}qI=PF0*8X> @ l  ٲ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <(}       TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT TestMethodLimits  Appearance [***] [***]' Estradiol Assay (10 ?g/capsule) [***] [***]) !Related Compounds (Tested at RTP) [***] [***]   [***]   [***] [***] [***] Dissolution [***] [***] [***] [***] [***]Moisture Content [***] [***]!Total Aerobic Plate Count [***] [***]%Total Combined Yeast and Mold [***] [***] P. aeruginosa [***] [***] S. aureus [***] [***]Candida albicans [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/B~XwC oFi@G W=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <(}       TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT TestMethodLimits  Appearance [***] [***]' Estradiol Assay (25 ?g/capsule) [***] [***]) !Related Compounds (Tested at RTP) [***] [***]   [***]   [***] [***] [***] Dissolution [***] [***] [***] [***] [***]Moisture Content [***] [***]!Total Aerobic Plate Count [***] [***]%Total Combined Yeast and Mold [***] [***] P. aeruginosa [***] [***] S. aureus [***] [***]Candida albicans [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/B~XwC oFi@G W=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} } a      TherapeuticsMD, Inc. 10-Q 07/30/20182*UNIT PRICING, FEES AND MINIMUM REQUIREMENT/'UNIT PRICING- Theoretical Batch Size of# [***] softgels per strength3 +Any Volume- Lot size to be phased out after/ 'first Contract Year based on validation of larger batch size Product  Unit Strength Initial Unit Price Softgel OvuleEstradiol 25 mcg$[***] Softgel OvuleEstradiol 10 mcg$[***] Softgel OvuleEstradiol 4 mcg$[***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0xl`T!p&RF:=PF0*8X> @B     l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} } 0.      TherapeuticsMD, Inc. 10-Q 07/30/20182*UNIT PRICING, FEES AND MINIMUM REQUIREMENT/'UNIT PRICING- Theoretical Batch Size of' 1,200,000 softgels per strength3 +Tier 1 Volume: [***] Total Softgels Shipped in Calendar Year Product  Unit Strength Initial Unit Price  Softgel Ovule Estradiol 25 mcg $[***] Softgel OvuleEstradiol 10 mcg$[***] Softgel OvuleEstradiol 4 mcg$[***]0(Tier 2 Volume: Over [***] Total Softgels Shipped in Calendar YearProduct Unit Strength.&Initial Unit Price For All IncrementalVolume Over [***] Softgel OvuleEstradiol 25 mcg$[***] Softgel OvuleEstradiol 10 mcg$[***] Softgel OvuleEstradiol 4 mcg$[***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<xl`T!YQ-S =PF0*8X> @J     l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} }       TherapeuticsMD, Inc. 10-Q 07/30/20182*UNIT PRICING, FEES AND MINIMUM REQUIREMENTMINIMUM REQUIREMENT  Contract Year Product Minimum Requirement* [***]" Across all three strengths [***] Softgels [***]" Across all three strengths [***] Softgels [***]" Across all three strengths [***] Softgels [***]" Across all three strengths [***] Softgels [***]"Across all three strengths[***] Softgels [***]"Across all three strengths[***] Softgels$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.Jxl`T5GT=PF0*8X> @" l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } !} 1} I      TherapeuticsMD, Inc. 10-Q 07/30/20182*UNIT PRICING, FEES AND MINIMUM REQUIREMENTADDITIONAL FEES  Type of Fee Amount Payable Product Maintenance Fee1 )$[***] for the first strength; $[***] for [***]  each additional strength    # Hormone Suite Occupancy Fee1 )Waived based on minimum volume guarantees N/A$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*\hxl`T9X4=PF0*8X> @" l  =C  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3) EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <} 8}  =     TherapeuticsMD, Inc. 10-Q 07/30/2018Table of Contents Page ARTICLE 1 - DEFINITIONS~   Section 1.1 Certain Defined Terms~   Section 1.2+ #Accounting Terms and Determinations~ v  Section 1.36 .Other Definitional and Interpretive Provisions~ z  Section 1.4(  Settlement and Funding Mechanics~ z Section 1.5Time is of the Essence~ z Section 1.6 Time of Day~ zARTICLE 2 - LOANS~ z Section 2.1 Loans~ z Section 2.23+Interest, Interest Calculations and Certain~  Fees Section 2.3 Notes~  Section 2.4Reserved~  Section 2.5Reserved~  Section 2.6-%General Provisions Regarding Payment;~  Loan Account Section 2.7Maximum Interest~  Section 2.87/Taxes; Capital Adequacy; Mitigation Obligations~  Section 2.9.&Appointment of Borrower Representative~  Section 2.10.&Joint and Several Liability; Rights of~ 3+Contribution; Subordination and Subrogation Section 2.11/'Termination; Restriction on Termination~ 2*ARTICLE 3 - REPRESENTATIONS AND WARRANTIES~ Dd lymEzGn8pL T !"#$%&'()*+,-./0123456789:;<  Section 3.1 Existence and Power~ ! Section 3.24!,Organization and Governmental Authorization;~ !""No Contravention# Section 3.3#Binding Effect~ #$ Section 3.4$Capitalization~ $% Section 3.5%Financial Information~ %& Section 3.6& Litigation~ &' Section 3.7'Ownership of Property~ '( Section 3.8( No Default~ () Section 3.9) Labor Matters~ )* Section 3.10*Regulated Entities~ *+ Section 3.11+Margin Regulations~ +, Section 3.12,,$Compliance With Laws; Anti-Terrorism~ ,- -Laws. Section 3.13 .Taxes~ ./ Section 3.14/Compliance with ERISA~ /0 Section 3.150Brokers~ 01 Section 3.161Reserved~ 12 Section 3.172Material Contracts~ 23 Section 3.1833+Compliance with Environmental Requirements;~ 344No Hazardous Materials5 Section 3.1945,Intellectual Property and License Agreements~ 56 Section 3.206Solvency~ 67 Section 3.217Full Disclosure~ 789$:____________________________1;)Created by Morningstar Document Research.0<(http://documentresearch.morningstar.com/> 0_7s8y5HJa'=PF0*8X> @2<<;;::  l  ;B1f:  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } <} 6} $ ;     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Section 3.22 Subsidiaries~   Section 3.23 Regulatory Matters~ ) !ARTICLE 4 - AFFIRMATIVE COVENANTS~   Section 4.1. &Financial Statements and Other Reports~   Section 4.2. &Payment and Performance of Obligations~   Section 4.3 Maintenance of Existence~  Section 4.4*"Maintenance of Property; Insurance~  Section 4.53+Compliance with Laws and Material Contracts~  Section 4.61)Inspection of Property, Books and Records~  Section 4.7Use of Proceeds~  Section 4.8Reserved~  Section 4.9Reserved~  Section 4.10)!Hazardous Materials; Remediation.~  Section 4.11Further Assurances~  Section 4.12Reserved~  Section 4.13Power of Attorney~  Section 4.14,$Intellectual Property and Licensing.~  Section 4.15Regulatory Covenants~ &ARTICLE 5 - NEGATIVE COVENANTS~  Section 5.1$Debt; Contingent Obligations~  Section 5.2 Liens~  Section 5.3 Distributions~  Section 5.4Restrictive Agreements~  Section 5.52*Payments and Modifications of Subordinated~ D lw9c pzAq7X _ !"#$%&'()*+,-./0123456789:  Debt! Section 5.64!,Consolidations, Mergers and Sales of Assets;~ !""Change in Control# Section 5.7'#Purchase of Assets, Investments~ #$ Section 5.8$$Transactions with Affiliates~ $% Section 5.90%(Modification of Organizational Documents~ %& Section 5.10*&"Modification of Certain Agreements~ &' Section 5.11'Conduct of Business~ '( Section 5.12&(Excluded Foreign Subsidiaries.~ () Section 5.135)-Limitation on Sale and Leaseback Transactions~ )* Section 5.141*)Deposit Accounts and Securities Accounts;~ *+%+Payroll and Benefits Accounts, Section 5.15+,#Compliance with Anti-Terrorism Laws~ ,- Section 5.16-Change in Accounting~ -. Section 5.17.Investment Company Act~ .'/ARTICLE 6 - FINANCIAL COVENANTS~ /0 Section 6.10Minimum Net Revenue~ 01 Section 6.21Minimum Liquidity~ 1 2 Section 6.32Evidence of Compliance~ 2 3ARTICLE 7 - CONDITIONS~ 3 4 Section 7.14Conditions to Closing~ 4 5 Section 7.25Conditions to Each Loan~ 567$8____________________________19)Created by Morningstar Document Research.0:(http://documentresearch.morningstar.com/:^h ;t0w1=PF0*8X> @:::998833//  l  ;yMzV  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} U5} $ ;     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Section 7.3Searches~   Section 7.4! Post-Closing Requirements~  ARTICLE 8 - RESERVED~ & ARTICLE 9 - SECURITY AGREEMENT~   Section 9.1  Generally~   Section 9.24 ,Representations and Warranties and Covenants~ Relating to Collateral&ARTICLE 10 - EVENTS OF DEFAULT~ " Section 10.1Events of Default~ " Section 10.22*Acceleration and Suspension or Termination~ .of Term Loan Commitment Section 10.3 UCC Remedies~ . Section 10.4Reserved~ 6 Section 10.5 Default Rate of Interest~ 6 Section 10.6 Setoff Rights~ 6 Section 10.7Application of Proceeds~ 6 Section 10.8Waivers~ : Section 10.9Injunctive Relief~ B Section 10.10'Marshalling; Payments Set Aside~ BARTICLE 11 - AGENT~ B Section 11.1%Appointment and Authorization~ B Section 11.2Agent and Affiliates~ B Section 11.3Action by Agent~ F Section 11.4!Consultation with Experts~ FD" lw>TNKy@0 !"#$%&'()*+,-./0123456789:  Section 11.5 Liability of Agent~ F! Section 11.6!Indemnification~ !F" Section 11.70"(Right to Request and Act on Instructions~ "J# Section 11.8#Credit Decision~ #J$ Section 11.9$Collateral Matters~ $J% Section 11.10%Agency for Perfection~ %J& Section 11.11&Notice of Default~ &N' Section 11.122'*Assignment by Agent; Resignation of Agent;~ 'N((Successor Agent) Section 11.13&)Payment and Sharing of Payment~ )R* Section 11.14.*&Right to Perform, Preserve and Protect~ *V+ Section 11.15 +Additional Titled Agents~ +V, Section 11.16,Amendments and Waivers~ ,V- Section 11.17&-Assignments and Participations~ -Z. Section 11.184.,Funding and Settlement Provisions Applicable~ .f/&/When Non-Funding Lenders Exist"0ARTICLE 12 - MISCELLANEOUS~ 0f1 Section 12.11Survival~ 1f2 Section 12.22 No Waivers~ 2j3 Section 12.33Notices.~ 3j4 Section 12.44 Severability~ 4n5 Section 12.55Headings~ 5n67$8____________________________19)Created by Morningstar Document Research.0:(http://documentresearch.morningstar.com/:{!T;Nh4F =PF0*8X> @B::998800   l  g  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} 1} $      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Section 12.6Confidentiality~ n  Section 12.71 )Waiver of Consequential and Other Damages~ r  Section 12.81 )GOVERNING LAW; SUBMISSION TO JURISDICTION~ r  Section 12.9 WAIVER OF JURY TRIAL~ r  Section 12.10" Publication; Advertisement~ v  Section 12.11! Counterparts; Integration~ v Section 12.12No Strict Construction~ v Section 12.13Lender Approvals~ v Section 12.14Expenses; Indemnity~ z Section 12.15Reserved~ ~ Section 12.16 Reinstatement~ ~ Section 12.17Successors and Assigns~ ~ Section 12.18$USA PATRIOT Act Notification~  Section 12.19.&Acknowledgement and Consent to Bail-In~ %of EEA Financial Institutions$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:w6:XT c."=PF0*8X> @ l  v  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } a/      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Exhibit A&Form of Compliance Certificate  Exhibit B# Form of Notice of Borrowing  Exhibit C$ Form of Payment Notification  Exhibit D-1/ 'Form of U.S. Tax Compliance Certificate  Exhibit D-2/ 'Form of U.S. Tax Compliance Certificate  Exhibit D-3/ 'Form of U.S. Tax Compliance Certificate Exhibit D-4/'Form of U.S. Tax Compliance Certificate Exhibit EClosing Checklist$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.w8u+eYM%=PF0*8X> @ l  '  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } 0 '     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Schedule 2.1-%Scheduled Principal Payments for Term  Loan  Schedule 3.1- %Existence, Organizational ID Numbers, * "Foreign Qualification, Prior Names  Schedule 3.4 Capitalization  Schedule 3.6  Litigation Schedule 3.17Material Contracts Schedule 3.18 Environmental Compliance Schedule 3.19Intellectual PropertySchedule 4.1(o),$Litigation, Governmental Proceedingsand Other Notice Events Schedule 4.150(Products and Regulatory Required Permits Schedule 5.1$Debt; Contingent Obligations Schedule 5.2 Liens Schedule 5.7Permitted Investments Schedule 5.8Affiliate Transactions Schedule 5.11Business Description Schedule 5.140(Deposit Accounts and Securities Accounts Schedule 6.1Minimum Net Revenue Schedule 7.2.&Term Loan Tranche 2 Funding Conditions Schedule 7.4 Post-Closing Obligations Schedule 9.1 CollateralSchedule 9.2(b)Location of CollateralSchedule 9.2(d)/'Chattel Paper, Letter of Credit Rights,Dlw.]/6zQX!m !"#$%& , $Commercial Tort Claims, Instruments,!&!Documents, Investment Property"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/xvN=PF0*8X> @&&%%$$ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } y#} -} 1} -} 1} -} 1      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITLender-%Term Loan Tranche 1 Commitment Amount1)Term Loan Tranche 1 Commitment Percentage-%Term Loan Tranche 2 Commitment Amount1)Term Loan Tranche 2 Commitment Percentage-%Term Loan Tranche 3 Commitment Amount1)Term Loan Tranche 3 Commitment Percentage MidCap Financial Trust~   0.000000%~   48.750000%~ b  48.750000% MidCap Funding VI Trust~ $  28.750000%~   0.000000%~   0.000000%! MidCap Funding XIII Trust~   20.000000%~   0.000000%~   0.000000%% Apollo Investment Corporation~ J]  30.000000%~ J]  30.000000%~   30.000000%# CION Investment Corporation~   20.000000%~   20.000000%~ Zb  20.000000%#Flexpoint MCLS Holdings LLC~ r89 1.250000%~ r89 1.250000%~ %& 1.250000%TOTALS~  100%~  100%~   100%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.w3bfZN&=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcSchedule 7 attached hereto or as Borrowers have previously reported to Agent on any Schedule7 to an Sincerely,    ! [BORROWER REPRESENTATIVE]     By:   Name: Title:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,3|?3'Y0=PF0*8X> @*  l  {  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcIN WITNESS WHEREOF, the undersigned officer has executed and delivered this Notice of Borrowing thi Sincerely,    ! [BORROWER REPRESENTATIVE]     By:   Name: Title:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,3|?3'Y0=PF0*8X> @*  l  i  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $ } } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcIN WITNESS WHEREOF, the undersigned officer has executed and delivered this Payment Notification th Sincerely,    ! [BORROWER REPRESENTATIVE]     By:   Name: Title:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,3|?3'Y0=PF0*8X> @*  l  $  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } I } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcBorrower Representative ), pursuant to that certain Credit and Security Agreement dated as of May 1[NAME OF LENDER]    By:   Name:   Title:   Date: , 20[ ] $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h?3'U% =PF0*8X> @" l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } I } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcBorrower Representative ), pursuant to that certain Credit and Security Agreement dated as of May 1[NAME OF PARTICIPANT]    By:   Name:   Title:   Date: , 20[ ] $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h?3'zP =PF0*8X> @" l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } I } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcBorrower Representative ), pursuant to that certain Credit and Security Agreement dated as of May 1[NAME OF PARTICIPANT]    By:   Name:   Title:   Date: , 20[ ] $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h?3'zP =PF0*8X> @" l  A  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } I } $      TherapeuticsMD, Inc. 10-Q 07/30/2018kcBorrower Representative ), pursuant to that certain Credit and Security Agreement dated as of May 1[NAME OF LENDER]    By:   Name:   Title:   Date: , 20[ ] $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h?3'U% =PF0*8X> @" l  O  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } +}  } } } 0      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITBorrower Prior NamesType of Entity /States QualifiedFederal Tax ID NumberLocation of Borrower   State of    (address)    Formation TherapeuticsMD, Inc. None Nevada All other states  87-02335350 (6800 Broken Sound Parkway NW, Suite 300,      Boca Raton, FL 33487  VitaMedMD LLC None Delaware FL  26-27044760 (6800 Broken Sound Parkway NW, Suite 300,Boca Raton, FL 33487BocaGreenMD, Inc. NoneNevada FL 45-48375810(6800 Broken Sound Parkway NW, Suite 300,Boca Raton, FL 33487,$VitaCare Prescription Services, Inc. NoneFlorida 47-42209650(6800 Broken Sound Parkway NW, Suite 300,Boca Raton, FL 33487$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4)wzMIXe`TH =PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9) PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } +} $4} } $4      TherapeuticsMD, Inc. 10-Q 07/30/2018#Schedule 3.4 CapitalizationIssuer3+Class of capital Stock Issued or MembershipHolder3+Capital Stock/Membership Interest Ownership  Interest  VitaMedMD LLC Membership Interest TherapeuticsMD, Inc. 100% BocaGreenMD, Inc.  Common Stock TherapeuticsMD, Inc. 100%, $VitaCare Prescription Services, Inc.  Common Stock TherapeuticsMD, Inc. 100% $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T{ocIl`T,=PF0*8X> @ l  'V2w4  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} m} } U} I '     TherapeuticsMD, Inc. 10-Q 07/30/2018PATENTS Patent Number TitleGrant/Country    Allowed Date (mm/dd/yy)~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~ " [***] [***] [***] [***]~ & [***] [***] [***] [***]~ * [***] [***] [***] [***]~ . [***] [***] [***] [***]~ 2 [***] [***] [***] [***]~ 6 [***] [***] [***] [***]~ : [***] [***] [***] [***]~ > [***] [***] [***] [***]~ B [***] [***] [***] [***]~ F [***] [***] [***] [***]~ J [***] [***] [***] [***]~ N [***] [***] [***] [***]~ R [***] [***] [***] [***]~ V [***] [***] [***] [***]~ Z [***] [***] [***] [***]D lw1;EOYcm !"#$%&~ ^ [***] [***] [***] [***]~ !b ![***] ![***] ![***] ![***]"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/x\PD=PF0*8X> @&&%%$$ l  iF  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U} m} } U} I      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Patent Number TitleGrant/Country    Allowed Date (mm/dd/yy)~ f [***] [***] [***] [***]~ j [***] [***] [***] [***]~ n [***] [***] [***] [***]~ r [***] [***] [***] [***]~ v [***] [***] [***] [***]~ z [***] [***] [***] [***]~ ~ [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<.w1;EOk=PF0*8X> @ l  ',[M]  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} a} } } I '     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplication Number TitleApplication DateCountry~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~ " [***] [***] [***] [***]~ & [***] [***] [***] [***]~ * [***] [***] [***] [***]~ . [***] [***] [***] [***]~ 2 [***] [***] [***] [***]~ 6 [***] [***] [***] [***]~ : [***] [***] [***] [***]~ > [***] [***] [***] [***]~ B [***] [***] [***] [***]~ F [***] [***] [***] [***]~ J [***] [***] [***] [***]~ N [***] [***] [***] [***]~ R [***] [***] [***] [***]~ V [***] [***] [***] [***]~ Z [***] [***] [***] [***]~ ^ [***] [***] [***] [***]D lw is!}+5?IS !"#$%&~ b [***] [***] [***] [***]~ !f ![***] ![***] ![***] ![***]"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/x\PD=PF0*8X> @&&%%$$ l  *q9u  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U} a} } } I *     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplication Number TitleApplication DateCountry~ j [***] [***] [***] [***]~ n [***] [***] [***] [***]~ r [***] [***] [***] [***]~ v [***] [***] [***] [***]~ z [***] [***] [***] [***]~ ~ [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]D lw is!}+5?IS !"#$%&'()~  [***] [***] [***] [***]~ ! ![***] ![***] ![***] ![***]~ " "[***] "[***] "[***] "[***]~ # #[***] #[***] #[***] #[***]~ $ $[***] $[***] $[***] $[***]%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/ \ fZN&=PF0*8X> @))(('' l  *؉+  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U} a} } } I *     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplication Number TitleApplication DateCountry~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~ " [***] [***] [***] [***]~ & [***] [***] [***] [***]~ * [***] [***] [***] [***]~ . [***] [***] [***] [***]~ 2 [***] [***] [***] [***]D lw is!}+5?IS !"#$%&'()~ 6 [***] [***] [***] [***]~ !: ![***] ![***] ![***] ![***]~ "> "[***] "[***] "[***] "[***]~ #B #[***] #[***] #[***] #[***]~ $F $[***] $[***] $[***] $[***]%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/ \ fZN&=PF0*8X> @))(('' l  *ʡ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } U} a} } } I *     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplication Number TitleApplication DateCountry~ J [***] [***] [***] [***]~ N [***] [***] [***] [***]~ R [***] [***] [***] [***]~ V [***] [***] [***] [***]~ Z [***] [***] [***] [***]~ ^ [***] [***] [***] [***]~ b [***] [***] [***] [***]~ f [***] [***] [***] [***]~ j [***] [***] [***] [***]~ n [***] [***] [***] [***]~ r [***] [***] [***] [***]~ v [***] [***] [***] [***]~ z [***] [***] [***] [***]~ ~ [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]D lw is!}+5?IS !"#$%&'()~  [***] [***] [***] [***]~ ! ![***] ![***] ![***] ![***]~ " "[***] "[***] "[***] "[***]~ # #[***] #[***] #[***] #[***]~ $ $[***] $[***] $[***] $[***]%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/ \ fZN&=PF0*8X> @))(('' l  $v  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } a} } } I $     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplication Number TitleApplication DateCountry~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]D lw is!}+5?IS !"# $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/ <=PF0*8X> @##""!! l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15)TRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} } 0} I      TherapeuticsMD, Inc. 10-Q 07/30/2018 TRADEMARKSRegistration NumberTrademark or DesignRegistration DateCountry     (mm/dd/yy)~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~ " [***] [***] [***] [***]~ & [***] [***] [***] [***]~ * [***] [***] [***] [***]~ . [***] [***] [***] [***]~ 2 [***] [***] [***] [***]~ 6 [***] [***] [***] [***]~ : [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0tnx&0:D8,=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKS EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} m} }  } I      TherapeuticsMD, Inc. 10-Q 07/30/2018 TRADEMARKS Serial NumberTrademark or Design Filing DateCountry     (mm/dd/yy)~  [***] [***] [***] [***]~   [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]~  [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|tz(2&=PF0*8X> @ l  >  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} m} }  } I      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Serial NumberTrademark or Design Filing DateCountry     mm/dd/yy)~  [***] [***] [***] [***]~  [***] [***] [***] [***]~ " [***] [***] [***] [***]~ & [***] [***] [***] [***]~ * [***] [***] [***] [***]~ . [***] [***] [***] [***]~ 2 [***] [***] [***] [***]~ 6 [***] [***] [***] [***]~ : [***] [***] [***] [***]~ > [***] [***] [***] [***]~ B [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8gw ~,6@J>2 =PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } $} } $} 0} I      TherapeuticsMD, Inc. 10-Q 07/30/2018 SERVICE MARKSRegistration NumberService Mark or DesignRegistration DateCountry     (mm/dd/yy)~  [***] [***] [***] [***]~   [***] [***] [***] [***]  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@}qh =PF0*8X> @ l  x   dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } } <} } 2      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Bank NameAccount Number Account TypeBranch Address2*Name of Company/Subsidiary holding Account [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2w678=PF0*8X> @ l  !g  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 6}  !     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITDefined Period EndingMinimum Net Revenue September 30, 2018 [***] December 31, 2018 [***] March 31, 2019 [***]  June 30, 2019 [***] September 30, 2019 [***]December 31, 2019 [***]March 31, 2020 [***] June 30, 2020 [***]September 30, 2020 [***]December 31, 2020 [***]March 31, 2021 [***] June 30, 2021 [***]September 30, 2021 [***]December 31, 2021 [***]March 31, 2022 [***] June 30, 2022 [***]September 30, 2022 [***]December 31, 2022 [***]5-March 31, 2023 and each Defined Period ending [***] thereafter$____________________________1)Created by Morningstar Document Research.D7lw7V(vK!o@ 0 (http://documentresearch.morningstar.com/H=PF0*8X> @  l  !-J.  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 6}  !     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITDefined Period EndingMinimum Net Revenue September 30, 2018 [***] December 31, 2018 [***] March 31, 2019 [***]  June 30, 2019 [***] September 30, 2019 [***]December 31, 2019 [***]March 31, 2020 [***] June 30, 2020 [***]September 30, 2020 [***]December 31, 2020 [***]March 31, 2021 [***] June 30, 2021 [***]September 30, 2021 [***]December 31, 2021 [***]March 31, 2022 [***] June 30, 2022 [***]September 30, 2022 [***]December 31, 2022 [***]5-March 31, 2023 and each Defined Period ending [***] thereafter$____________________________1)Created by Morningstar Document Research.D7lw7V(vK!o@ 0 (http://documentresearch.morningstar.com/H=PF0*8X> @  l  ! ??  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 6}  !     TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITDefined Period EndingMinimum Net Revenue September 30, 2018 [***] December 31, 2018 [***] March 31, 2019 [***]  June 30, 2019 [***] September 30, 2019 [***]December 31, 2019 [***]March 31, 2020 [***] June 30, 2020 [***]September 30, 2020 [***]December 31, 2020 [***]March 31, 2021 [***] June 30, 2021 [***]September 30, 2021 [***]December 31, 2021 [***]March 31, 2022 [***] June 30, 2022 [***]September 30, 2022 [***]December 31, 2022 [***]5-March 31, 2023 and each Defined Period ending [***] thereafter$____________________________1)Created by Morningstar Document Research.D7lw7V(vK!o@ 0 (http://documentresearch.morningstar.com/H=PF0*8X> @  l  =N  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } m} } U} I      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Patent Number TitleGrant/Country   Allowed Date (mm/dd/yy) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.w(e!UI==PF0*8X> @ l  \  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } a} }  } I      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITApplicatIon Number Title Filing dateCountry [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TwR=PF0*8X> @ l  ]i  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } 7} y      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT6.Complete Street and Mailing Address, includingBorrower County and Zip Code [***] [***] [***] [***] [***] [***] [***] [***]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hw) vjB=PF0*8X> @ l  u  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } y      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBITComplete AddressBorrower [***] [***] [***] [***]  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,wG%=PF0*8X> @  l  $  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } } 7} a      TherapeuticsMD, Inc. 10-Q 07/30/2018EXHIBIT Name6.Complete Street and Mailing Address, includingCompany/Subsidiary  County and Zip Code [***] [***] [***] [***] [***] [***]  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@w~rf>=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25) IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } }       TherapeuticsMD, Inc. 10-Q 07/30/2018e]IN WITNESS WHEREOF, the parties have executed this Lease as of the last date set forth below.STATE OF Florida )  ) ss: COUNTY OF Palm Beach )  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$;,E9-!n=PF0*8X> @  l  Ü  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  Exhibit 311 Exhibit 312 Exhibit 321 Exhibit 322U } }       TherapeuticsMD, Inc. 10-Q 07/30/2018e]IN WITNESS WHEREOF, the parties have executed this Lease as of the last date set forth below.STATE OF Florida )  ) ss: COUNTY OF Palm Beach )  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$;,E9-!n=PF0*8X> @  l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 312 Exhibit 321 Exhibit 322U } m} $ } y#      TherapeuticsMD, Inc. 10-Q 07/30/2018 Exhibit 31.1 July 30, 2018/s/ Robert G. Finizio   Robert G. Finizio   Chief Executive Officer  % (Principal Executive Officer)  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@~r,{oc;=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 321 Exhibit 322U } m} $ } U5      TherapeuticsMD, Inc. 10-Q 07/30/2018 Exhibit 31.2 July 30, 2018 /s/ Daniel A. Cartwright   Daniel A. Cartwright   Chief Financial Officer  4 ,(Principal Financial and Accounting Officer)    $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T~r)fB6*=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 322U } m} y#      TherapeuticsMD, Inc. 10-Q 07/30/2018 Exhibit 32.1 July 30, 2018/s/ Robert G. Finizio  Robert G. Finizio  Chief Executive Officer % (Principal Executive Officer)  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&R@~r8k=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??PNA SIGNATURESItem 1 Financial StatementsIncome Statement Cash Flows!NOTE 3 SUMMARY OF SIGNIFICANT ANOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETSNOTE 7 INTANGIBLE ASSETS (1)!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (1)NOTE 10 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTE 15 COMMITMENTS AND CONTINGResearch and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Results of Operations (3)Results of Operations (4)Results of Operations (5)!Liquidity and Capital ResourcesItem 6 ExhibitsSIGNATURES (1)NOTICE!I Clientsupplied Materials and  EXHIBITProduct Specifications EXHIBIT (1) EXHIBIT (2)!UNIT PRICING FEES AND MINIMUM R!UNIT PRICING FEES AND MINIM (1)!UNIT PRICING FEES AND MINIM (2)!UNIT PRICING FEES AND MINIM (3)Table of Contents EXHIBIT (3) EXHIBIT (4) EXHIBIT (5) EXHIBIT (6) EXHIBIT (7) EXHIBIT (8)!Schedule 7 attached hereto or a!IN WITNESS WHEREOF the undersig!IN WITNESS WHEREOF the unde (1)!Borrower Representative pursuan!Borrower Representative pur (1)!Borrower Representative pur (2)!Borrower Representative pur (3) EXHIBIT (9)Schedule 34 Capitalization PATENTS EXHIBIT (10) EXHIBIT (11) EXHIBIT (12) EXHIBIT (13) EXHIBIT (14) EXHIBIT (15) TRADEMARKSTRADEMARKS (1) EXHIBIT (16) SERVICE MARKS EXHIBIT (17) EXHIBIT (18) EXHIBIT (19) EXHIBIT (20) EXHIBIT (21) EXHIBIT (22) EXHIBIT (23) EXHIBIT (24) EXHIBIT (25)!IN WITNESS WHEREOF the parties  IN WITNESS WHEREOF the par (1) Exhibit 311 Exhibit 312 Exhibit 321U } m} U5      TherapeuticsMD, Inc. 10-Q 07/30/2018 Exhibit 32.2 July 30, 2018 /s/ Daniel A. Cartwright  Daniel A. Cartwright  Chief Financial Officer 4 ,(Principal Financial and Accounting Officer)   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T~r5 ~rf>=PF0*8X> @ Root Entry FBook  B  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~